The following post comes from Austin Shaffer, a 2L at Scalia Law and a Research Assistant at CPIP. By Austin Shaffer In their new paper, Distorted Drug Patents, CPIP Senior […]
[Archived Post] Professor David Taylor on Patent Eligibility and Investment
The following post comes from Terence Yen, a 4E at Scalia Law and a Research Assistant at CPIP. By Terence Yen In his new paper, Patent Eligibility and Investment, Professor […]
[Archived Post] IP Scholars Question the Legality and Wisdom of Joint AG Proposal to Seize Remdesivir Patents
The following post comes from Colin Kreutzer, a 2E at Scalia Law and a Research Assistant at CPIP. By Colin Kreutzer While the vaccines are starting to roll out in […]
[Archived Post] Professor Joanna Shepherd Explains Pharmaceutical Product Hopping in New CPIP Policy Brief
CPIP has published a new policy brief by Joanna M. Shepherd, Vice Dean and Thomas Simmons Professor of Law at Emory University School of Law. The brief, entitled The Legal […]
[Archived Post] (Patented) Life Begins at Forty: CPIP Celebrates the Ongoing Legacy of Diamond v. Chakrabarty
The following post comes from Colin Kreutzer, a rising 2E at Scalia Law and a Research Assistant at CPIP. By Colin Kreutzer It’s been forty years since the Supreme Court […]
[Archived Post] Recent Developments in the Life Sciences: The Continuing Assault on Innovation by Antitrust Plaintiffs in Lantus
By Erika Lietzan In February, the U.S. Court of Appeals for the First Circuit held, in a direct purchaser antitrust action, that an innovative pharmaceutical company marketing an injectable drug […]
[Archived Post] IP Industries Step Up in This Time of Crisis
The global COVID-19 pandemic has challenged multiple aspects of modern society in a short time. Health and public safety, education, commerce, research, arts, and even basic government functions have had […]
[Archived Post] New CPIP Policy Brief: Barnett on the End of Patent Groupthink
In a new CPIP policy brief entitled The End of Patent Groupthink, CPIP Senior Fellow for Innovation Policy Jonathan Barnett highlights some cracks that have emerged in the recent policy […]
[Archived Post] “No Combination Drug Patents Act” Stalls, but Threats to Innovation Remain
By Kevin Madigan & Sean O’Connor This week, the Senate Judiciary Committee was to mark up a bill limiting patent eligibility for combination drug patents—new forms, uses, and administrations of […]
[Archived Post] Empirical Study Confirms Positive Relationship Among Patents, Technological Progress, and Societal Benefit
We “stand on the shoulder of giants,” goes the famous adage. In a groundbreaking new law review article, Does Patented Information Promote the Progress of Technology?, Cardozo Law’s Jonathan H. […]